Coppell Advisory Solutions’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
Other funds holding ADMA
RCMNY
CP
Coppell Advisory Solutions's ADMA Position: Q2 2026 in Review
Coppell Advisory Solutions reduced its ADMA Biologics (ADMA) stake by 40% in Q2 2026, selling an estimated $4K and leaving 670 shares worth $739K. The position accounts for 0.06% of the portfolio, ranked #230.
Coppell Advisory Solutions first reported a position in ADMA in Q2 2023 and has held it in 10 quarters since. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.
- Coppell Advisory Solutions held 670 shares of ADMA Biologics worth $739K as of Q2 2026.
- Coppell Advisory Solutions sold 439 ADMA Biologics shares in Q2 2026, an estimated $4K.
- ADMA Biologics made up 0.06% of Coppell Advisory Solutions's portfolio in Q2 2026, its #230 holding.
- Coppell Advisory Solutions first reported a position in ADMA Biologics in Q2 2023 and has held it in 10 quarters since.
- 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.
Based on Coppell Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.